Skip to main content
Mereo BioPharma Group plc logo

Mereo BioPharma Group plc — Investor Relations & Filings

Ticker · MREO ISIN · GB00BZ4G2K23 LEI · 213800U8JQHIJOS5AS09 US Manufacturing
Open in API
Filings indexed 635 across all filing types
Latest filing 2021-09-21 Regulatory Filings
Country GB United Kingdom
Listing US MREO

About Mereo BioPharma Group plc

https://www.mereobiopharma.com/

Mereo BioPharma Group plc is a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for rare diseases with limited or no treatment options. The company's strategy involves acquiring and advancing promising clinical-stage product candidates that have been de-prioritized by larger pharmaceutical or biotechnology companies. This capital-efficient model allows it to develop a specialized pipeline. Its two lead programs are setrusumab for the treatment of osteogenesis imperfecta (OI) and alvelestat for Alpha-1 antitrypsin deficiency-associated lung disease (AATD-LD). Mereo BioPharma also engages in strategic partnerships and out-licenses other clinical assets to deliver impactful treatments to patients.

Recent filings

Filing Released Lang Actions
Regulatory Filings 2021
Regulatory Filings Classification · 90% confidence The provided document text appears to be encoded or encrypted and does not contain any readable content, keywords, regulatory headers, or references to specific report types, fiscal periods, or regulatory bodies. Due to the lack of identifiable information and the inability to determine the nature of the document, it cannot be classified into any specific filing category. According to the fallback rule, such documents should be classified as Regulatory Filings (RNS). The document length is 15,000 characters, which is substantial, but the content is not interpretable.
2021-09-21 English
6-K
Board/Management Information Classification · 100% confidence The document is a Form 6-K filed by a foreign private issuer, Mereo BioPharma Group PLC, with the SEC. It includes a press release announcing the appointment of a new board member, Pierre Jacquet, M.D., Ph.D., to the Board of Directors. The content is an announcement of a management change rather than a full report or financial statement. The document length is short (1479 characters), and it is clearly about a board appointment, which fits the category of Board/Management Information (MANG).
2021-09-20 English
Regulatory Filings 2021
Regulatory Filings Classification · 95% confidence The document is a letter from Mayer Brown LLP responding to comments from the SEC staff regarding a Registration Statement on Form F-3 filed by Mereo BioPharma Group plc. The content focuses on legal analysis and clarifications about the registration of resale shares issuable to AstraZeneca AB, referencing specific SEC rules and compliance interpretations. It is a correspondence related to a regulatory filing process rather than a financial report, earnings release, or other types of filings. The document does not contain financial statements or detailed financial data but is a legal response to SEC comments on a registration statement. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory correspondence and compliance documents that do not fit other specific categories.
2021-09-07 English
F-3/A
Capital/Financing Update Classification · 100% confidence The document is an Amendment No. 1 to Form F-3 Registration Statement filed with the SEC under the Securities Act of 1933. It includes detailed information about the registration of securities, including primary and secondary offerings, registration fees, and prospectus details. The Form F-3 is a registration statement used by companies to register securities for public offering. This document is not a financial report, earnings release, or management discussion, but rather a capital markets filing related to securities registration and offering. Therefore, it fits the category of Capital/Financing Update (CAP). The document length is substantial (15,000 characters), and it contains the full registration statement text, not just an announcement or notice, confirming it is a substantive filing about capital raising activities.
2021-09-07 English
Regulatory Filings 2021
Regulatory Filings Classification · 95% confidence The provided document text appears to be encoded or encrypted and does not contain any readable content, keywords, regulatory headers, fiscal period dates, or document titles that would allow identification of a specific filing type. The text does not include any indication of being a report, announcement, certification, or any other specific filing category. Given the lack of identifiable information and the fallback rule, the document should be classified as a Regulatory Filing (RNS), which serves as a general category for miscellaneous filings that do not fit other specific types.
2021-08-21 English
Regulatory Filings 2021
Regulatory Filings Classification · 95% confidence The document is a Form F-6 Registration Statement filed with the SEC, which is used to register American Depositary Shares (ADSs) evidenced by American Depositary Receipts (ADRs). It includes details about the securities to be registered, the deposit agreement, signatures of officers and directors, and exhibits related to the depositary shares. This is a regulatory filing related to the registration of securities for trading in the U.S. market, not a financial report, earnings release, or management discussion. It is not an announcement of a report but the actual registration statement document. Therefore, it fits best under the category of Regulatory Filings (RNS), which is the fallback for miscellaneous SEC filings that do not fit other categories.
2021-08-13 English

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.